Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

British Journal of Cancer

Volumn 106, Issue 11, 2012, Pages 1766-1771

  Cummings, J ^a   Zweifel, M ^b   Smith, N ^a   Ross, P ^c   Peters, J ^c   Rustin, G ^b   Price, P ^d   Middleton, M R ^e   Ward, T ^a   Dive, C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cell death mechanisms; M30 ELISA; M65 ELISA; OXi4503; phase I trial; vascular disrupting agent

Indexed keywords

ANTIGEN; COMBRETASTATIN A1 PHOSPHATE; CYTOKERATIN 18; M30 ANTIGEN; M65 ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DEATH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DIPHOSPHATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KERATIN-18; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; STILBENES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861457284     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.165     Document Type: Article

References (35)

1. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC, Linder S (2003) A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8: 263-268 (Pubitemid 36749611)
2. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95: 42-48 (Pubitemid 43980552)
3. Cummings J, Ward TH, Dive C (2010) Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today 15: 816-825
4. Cummings J, Ward TH, Lacasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92: 532-538 (Pubitemid 40395534)
5. Dalal S, Burchill SA (2009) Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours. Eur J Cancer 45: 713-722
6. De Petris L, Branden E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtio J (2011) Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47: 131-137
7. Findlay JW (2008) Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution. Aaps J 10: 433-434
8. Fisher MB, Zhang XQ, McConkey DJ, Benedict WF (2009) Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Ther 16: 567-572
9. Folkes LK, Christlieb M, Madej E, Stratford MR, Wardman P (2007) Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 20: 1885-1894
10. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29: 909-916
11. Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C (2008) Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19: 990-995 (Pubitemid 351627319)
12. Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, Shoshan M, Linder S (2002) A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 20: 253-259 (Pubitemid 34823753)
13. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH (2009) Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175: 808-816
14. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, Edvardsen K (2003) Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23: 1433-1440 (Pubitemid 36754111)
15. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756 (Pubitemid 38428698)
16. Ku NO, Liao J, Omary MB (1997) Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272: 33197-33203 (Pubitemid 28023666)
17. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD (2005) Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105: 526-532 (Pubitemid 40070731)
18. Leers MP, Bjorklund V, Bjorklund B, Jornvall H, Nap M (2002) An immunohistochemical study of the clearance of apoptotic cellular fragments. Cell Mol Life Sci 59: 1358-1365
19. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572 (Pubitemid 29151999)
20. Lickliter JD, Francesconi AB, Smith G, Burge M, Coulthard A, Rose S, Griffin M, Milne R, McCarron J, Yeadon T, Wilks A, Cubitt A, Wyld DK, Vasey PA (2010) Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br J Cancer 103: 597-606
21. Linder S, Olofsson MH, Herrmann R, Ulukaya E (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10: 353-359
22. Merjava S, Neuwirth A, Mandys V, Jirsova K (2009) Cytokeratins 8 and 18 in adult human corneal endothelium. Exp Eye Res 89: 426-431
23. Miettinen M, Fetsch JF (2000) Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis. Hum Pathol 31: 1062-1067
24. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13: 3198-3206 (Pubitemid 46944902)
25. Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M (2009) Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 9: 645-648
26. Patterson DM, Ross P, Koetz B, Saleem A, Stratford M, Stirling J, Padhani A, Asselin M, Price P, Rustin GJ (2007) Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours. J Clin Oncol 25: 14146
27. Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ (2012) Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 18: 1415-1425
28. Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW (2011) Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvasc Res 81: 44-51
29. Schutte B, Henfling M, Kolgen W, Bouman M, Meex S, Leers MP, Nap M, Bjorklund V, Bjorklund P, Bjorklund B, Lane EB, Omary MB, Jornvall H, Ramaekers FC (2004) Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297: 11-26 (Pubitemid 38759558)
30. Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101: 410-417
31. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K (2004) Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 111: 604-610 (Pubitemid 39045329)
32. Stosiek P, Kasper M, Conrad K (1990) [Immunohistochemistry of cytokeratin expression in human blood vessel endothelia with special reference to synovial connective tissue]. Acta Histochem 89: 61-66
33. Strnad P, Windoffer R, Leube RE (2002) Induction of rapid and reversible cytokeratin filament network remodeling by inhibition of tyrosine phosphatases. J Cell Sci 115: 4133-4148 (Pubitemid 35446809)
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
35. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M (2007) The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56: 399-404 (Pubitemid 46679086)